Positive Results From Small Study Assessing The Safety Of LDN, UK

Results from a small study of Low Dose Naltrexone (LDN) have been published in the journalMultiple Sclerosis. The study headed by Dr. Gianvito Martino from the San Raffaele Hospital in Milan, Italy involved 40 people with primary progressive MS in an open label trial which aimed to make sure LDN was safe and well tolerated.

The results show that LDN is safe for people with MS. The trial also took an initial look at pain, fatigue, depression and spasticity in people with MS and the results suggested a beneficial effect of LDN on spasticity.

Dr Laura Bell, Research Communication Officer at the MS Society said, 'As with all drugs, there is a long way to go in terms of rigorous large scale clinical trials held over a number of years to determine if LDN would be safe and more effective than treatments currently available. But the results of this small pilot study is an important initial step and we await results from further studies with interest.'

MS Society